118631 20230519145536.0 doi 10.3390/life11070617 sideral 126878 ART-2021-126878 eng Marron S.E. Patient reported outcome measure in atopic dermatitis patients treated with dupilumab: 52-weeks results 2021 Access copy available to the general public Unrestricted Dupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. The outcomes were evaluated and registered at baseline and weeks 16, 40 and 52. The variables evaluated were: disease severity, pruritus, stressful life events, difficulty to sleep, anxiety and depression, quality of life, satisfaction, adherence to the treatment, efficacy and safety. Eleven patients were recruited between 14 Nov 2017 and 16 Jan 2018. Demographic variables: 90% Caucasian, 82% women. Clinical variables: Mean duration of AD = 17.7 (±12.8), 91% had severe disease severity. At baseline, SCORAD median (range) score = 69.2 (34.8–89.2); itch was reported by 100% of patients; itch visual analogue scale median (range) was 9 (6–10); HADS median (range) total score = 13 (5–21); DLQI mean score = 16 (2–27); EQ-5D-3L median (range) = 57 (30–99). At week- 52 there was a significant reduction of SCORAD scores median (range) = 4.3 (0–17.1), HADS total score median (range) = 2 (0–10) and improved quality of life EQ-5D-3L median (range) = 89 (92–60). This study confirms that dupilumab, used for 52-weeks under routine clinical practice, maintains the improved atopic dermatitis signs and symptoms obtained at week 16, with a good safety profile. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 3.253 2021 BIOLOGY 39 / 94 = 0.415 2021 Q2 T2 0.588 2021 Biochemistry, Genetics and Molecular Biology (miscellaneous) 2021 Q2 Space and Planetary Science 2021 Q2 Ecology, Evolution, Behavior and Systematics 2021 Q2 1.9 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Tomás Aragonés, L. Universidad de Zaragoza (orcid)0000-0003-1917-6906 Moncin-torres C.A. Gomez-barrera M. de Aranibar F.J.G.-L. 4009 735 Universidad de Zaragoza Dpto. Psicología y Sociología Área Psicolog.Evolut.Educac 11, 7 (2021), 617 [14 pp] Life (Basel) Life 2075-1729 2221230 http://zaguan.unizar.es/record/118631/files/texto_completo.pdf Versión publicada 2679254 http://zaguan.unizar.es/record/118631/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:118631 articulos driver 2023-05-18-15:35:51 ARTICLE